| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6113906 | BAUSCH AND LOMB INC | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(10 years ago) | |
| US5919455 | BAUSCH AND LOMB INC | Non-antigenic branched polymer conjugates |
Oct, 2013
(10 years ago) | |
| US6051698 | BAUSCH AND LOMB INC | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(8 years ago) | |
| US5932462 | BAUSCH AND LOMB INC | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(7 years ago) | |
| US6011020 | BAUSCH AND LOMB INC | Nucleic acid ligand complexes |
Jan, 2017
(7 years ago) | |
Macugen is owned by Bausch And Lomb Inc.
Macugen contains Pegaptanib Sodium.
Macugen has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Macugen are:
- US6113906
- US5919455
- US6051698
- US5932462
- US6011020
Macugen was authorised for market use on 17 December, 2004.
Macugen is available in injectable;intravitreal dosage forms.
Macugen can be used as treatment of vegf mediated ocular disease..
The generics of Macugen are possible to be released after 04 January, 2017.
Drugs and Companies using PEGAPTANIB SODIUM ingredient
Market Authorisation Date: 17 December, 2004
Treatment: Treatment of vegf mediated ocular disease.
Dosage: INJECTABLE;INTRAVITREAL
More Information on Dosage
MACUGEN family patents
